Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia

Sexual Health

Volumn 4, Issue 3, 2007, Pages 147-163

  Regan, David G ^a   Philp, David J ^b   Hocking, Jane S ^c   Law, Matthew G ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b The Australian National University   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cervical cancer; Dynamic transmission model; Herd immunity

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; AUSTRALIA; HERD IMMUNITY; HUMAN PAPILLOMAVIRUS TYPE 16; MATHEMATICAL MODEL; MORBIDITY; PREVALENCE; VACCINATION; VIRUS INFECTION; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AUSTRALIA; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; INCIDENCE; MALE; MASS IMMUNIZATION; MIDDLE AGED; MODELS, STATISTICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RISK FACTORS; SEXUAL BEHAVIOR; UTERINE CERVICAL NEOPLASMS;

EID: 34548316400     PISSN: 14485028     EISSN: None     Source Type: Journal    
DOI: 10.1071/SH07042     Document Type: Article

References (9)

1. Diekmann O, Heesterbeek JAP. Mathematical epidemiology of infectious diseases: model building, analysis and interpretation. Chichester, New York: Wiley; 2000.
2. Smith AMA, Rissel CE, Richters J, Grulich AE, de Visser RO. Sex in Australia: the rationale and methods of the Australian study of health and relationships. Aust NZ J Pub Health 2003; 27: 106-17.
3. Garnett GP, Anderson RM. Balancing sexual partnerships in an age and activity stratified model of HIV transmission in heterosexual populations. IMA J Math Appl Med Biol 1994; 11: 161-92. doi: 10.1093/imammb/11.3.161
4. Giuliano AR, Harris R, Sedjo RL, Baldwin S, Roe D, Papenfuss MR, et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the young women's health study. J Infect Dis 2002; 186: 462-9. doi: 10.1086/341782
5. Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004; 91: 942-53.
6. Lowndes CM. Vaccines for cervical cancer. Epidemiol Infect 2006; 134: 1-12. doi: 10.1017/S0950268805005728
7. Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnet GP. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006; 3: 624-32. doi: 10.1371/journal.pmed.0030138
8. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006; 107: 18-27.
9. Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan D, et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health 2007; 4: 165-75. doi: 10.1071/SH07043